Ultragenyx Pharmaceutical reported $136 million in total revenue for Q1 2026, with key products Crysvita and Dojolvi contributing $93 million and $18 million respectively. The company reaffirmed its 2026 revenue guidance of $730 million to $760 million and expects combined R&D and SG&A expenses to remain flat or slightly decrease compared to 2025. Ultragenyx highlighted promising long-term Phase 1/2 data for GTX-102 in treating Angelman syndrome, with Phase 3 results expected in the second half of 2026. The company is also progressing with regulatory reviews for gene therapies DTX401 and UX111, targeting approvals later this year, and aims for profitability in 2027.
A Kinder Morgan executive recently sold 5,695 shares of the company, totaling approximately $184,000, according to a recent SEC filing. This insider sale could indicate the executive's personal financial decision but does not necessarily reflect the ...
CoreWeave's stock rose nearly 18% after its Q2 results, recovering from a 51% drop from last summer's peak and a 34% fall from this year's high. The Q2 results beat low expectations but suggest the stock may gain more in the second half of the year d...
Bitcoin long-term holders now carry deeper unrealized losses than the broader market average, a rare sign typically seen near major cycle bottoms. Despite trading about 50% below its previous high, the losses have not yet reached the extreme levels o...
Kimberly-Clark is rated Buy due to its robust innovation pipeline, international expansion, and potential gains from the Kenvue acquisition. While facing temporary challenges in North America and China, these issues are expected to ease, with managem...
NovaRed Mining Inc. announced it will change its name to NRED Intelligent Mining Inc. effective August 17, 2026, to reflect its focus on integrating artificial intelligence into mineral exploration. The company will continue trading under the symbol ...
